hGIPR(SD)
Nomenclature
SD-Giprem1(hGIPR)Smoc
Cat. NO.
NR-HU-225067
Strain State
Repository Live
Gene Summary
Gene Symbol
Gipr
Model Description
Validation Data

Fig.1 Detection of GIPR expression in brain by RT-PCR.
Wild type: only one band at 177 bp with primers F1/R1(mGipr);
Homozygous: only one band at 343 bp with primers F2/R2(hGIPR).
Abbr. M, DNA marker; HO, homozygous; WT, wild type.

Fig. 2 Detection of human GIPR expression in hGIPR (SD) rats by WB.
Abbr. M,marker; HO, homozygous; WT, wild type; BAT, brown adipose tissue.
Note. The anti-human GIPR Antibody cross-reacted with rat GIPR and humanized GIPR.

Fig.3 In vivo function of hGIP in intraperitoneal glucose tolerance test (IPGTT). Administration of human GIP significantly lowered blood glucose levels after glucose injection in homozygous hGIPR knockin rats. These results suggest that the humanized GIPR is functionally responsive to human GIP in hGIPR knockin rats. (A) Concentration of blood glucose were measured after subcutaneous injection of 2g/kg glucose and 50 nmol/kg human GIP in 12 weeks old homozygous (HO) hGIPR male and female rats and (B) the area under the curve (AUC) was calculated. (2 males and 3 females in vehicle group and 2 males and 4 females in hGIP group, Mean ± SEM, Unpaired t-test, *p<0.05).

Fig.4 In vivo function of hGIP in intraperitoneal glucose tolerance test (IPGTT). Administration of human GIP significantly lowered blood glucose levels after glucose injection in homozygous hGIPR knockin rats. These results suggest that the humanized GIPR is functionally responsive to human GIP in hGIPR knockin rats. (A) Concentration of blood glucose were measured after subcutaneous injection of 2g/kg glucose and 50 nmol/kg human GIP in 12 weeks old homozygous (HO) hGIPR female rats and (B) the area under the curve (AUC) was calculated. (2 males and 3 females in vehicle group and 2 males and 4 females in hGIP group, Mean ± SEM, Unpaired t-test, *p<0.05).
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreSMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn more